Sanofi invests in mRNA Center of Excellence for vaccines
Mission is to expand its collection of mRNA vaccines beyond the Covid-19 pandemic
Sanofi will invest $476 million annually, as the big pharma looks to establish a vaccines mRNA Center of Excellence. The center’s goal is to speed up the development and delivery of next-generation vaccines—approximately 400 employees across the Cambridge, MA, and Marcy l’Etoile, Lyon (France), locations will be working toward the effort. The involved departments include research and development, digital, and chemistry, manufacturing and controls (CMC).
Specifically, the Center of Excellence will enable acceleration of the vaccines mRNA portfolio developed through the Translate Bio collaboration established in 2018 and expanded in 2020.
Operating Without a Commercial Blueprint: Empowering the Field for Niche Therapy Launches
October 24th 2024How emerging biotech companies can create fruitful partnerships between home office commercial teams and the field force to enable this intelligence gathering, while driving commercial success.
